Table 2. Cytogenetic/molecular risk and treatment outcome of 41 patients with AML, stratified by Twist1 expression level.
| Twist1 (+) | Twist1 (−) | P-value | |
|---|---|---|---|
| Cytogenetic risk | 0.222 | ||
| Good | 2 | 0 | |
| Intermediate | 15 | 16 | |
| Poor | 1 | 3 | |
| NPM1 mutation | 0.464 | ||
| Mutated | 7 | 3 | |
| Wild type | 15 | 15 | |
| FLT3 mutation | 1.000 | ||
| Mutated | 5 | 4 | |
| Wild type | 17 | 14 | |
| Molecular/cytogenetic risk | 0.031 | ||
| Good | 5 | 0 | |
| Intermediate | 15 | 13 | |
| Poor | 2 | 6 | |
| Achievement of CR | 0.013 | ||
| Yes | 13 | 6 | |
| No | 1 | 7 | |
| No. of chemo cycles to CR | 1.1±0.3 | 1.8±1.2 | 0.037 |
Abbreviations: AML, acute myeloid leukemia; CR, complete remission. P-values with statistically significant differences are shown in bold.